tazobactam has been researched along with Fever of Unknown Origin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T | 1 |
| Baudard, M; Bouvet, A; Chast, F; Delmer, A; Legrand, O; Levy, V; Marie, JP; Marjanovic, Z; Rio, B; Vekhoff, A; Zittoun, R | 1 |
2 trial(s) available for tazobactam and Fever of Unknown Origin
| Article | Year |
|---|---|
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibility; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Fever of Unknown Origin; Humans; Immunocompromised Host; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Penicillanic Acid; Piperacillin; Prospective Studies; Safety; Tazobactam; Treatment Outcome | 2004 |
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Bacteremia; Bacterial Infections; Case-Control Studies; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Fever of Unknown Origin; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Tobramycin; Vancomycin | 1999 |